Telum Therapeutics, a biotechnology company leveraging proprietary metagenomic datasets, synthetic biology and generative AI to develop novel antimicrobial therapies, today announced the successful completion of
A pioneering R&D project led by Telum Therapeutics, in collaboration with the Complutense University of Madrid (UCM) and the Carlos III Health Institute (ISCIII), has
Telum is pleased to announce the filing of a new patent for Telum’s proprietary modular library cloning system. This patent represents a significant advancement in
Navarra, Spain – January 24, 2025 – Telum Therapeutics, a global biotechnology company specializing in the development of engineered direct acting lytic proteins as novel antimicrobial
Pamplona, Spain – December 24, 2024– Telum Therapeutics, a leading biotechnology company specializing in drug discovery, is pleased to announce the filing of a new patent,
In observance of World Health Day on April 7th, Telum Therapeutics announces its membership in the United Nations Global Compact as a new participant. The
Telum Therapeutics announces the appointment of Subhendu Basu, PhD, as its new Chief Executive Officer (CEO). He joins the company to lead it into its
Telum Therapeutics has just received good news: a badge for its social, environmental and ethical commitment awarded by EcoVadis, the world’s most trusted provider of
Telum Therapeutics has joined the Treedom platform, which is part of the B corp community, to help create sustainable agroforestry ecosystems and fight climate change.
